Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice.
The effect of in vivo treatment with anti-L3T4 monoclonal antibody (mAb) on the course of experimentally-induced cutaneous leishmaniasis was studied in genetically susceptible BALB/c mice. Administration of anti-L3T4 mAb resulted in a pronounced therapeutic effect as reflected by both resolution of lesions and a dramatic reduction in the parasite load in treated mice. This effect was specific for anti-L3T4 mAb and correlated with a selective depletion of L3T4+ T cells in the lymphoid tissues of treated mice. Moreover, both the therapeutic effect of anti-L3T4 mAb on cutaneous leishmaniasis and the concurrent depletion of L3T4+ T cells in the lymphoid tissues of treated mice were dependent upon the isotype of the anti-L3T4 mAb employed.